Insmed Inc (INSM)
64.50
-1.84
(-2.77%)
USD |
NASDAQ |
Jul 02, 16:00
65.58
+1.08
(+1.67%)
After-Hours: 05:31
Insmed SG&A Expense (Annual): 344.50M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 344.50M |
| December 31, 2022 | 265.78M |
| December 31, 2021 | 234.27M |
| December 31, 2020 | 203.61M |
| December 31, 2019 | 210.80M |
| December 31, 2018 | 168.22M |
| December 31, 2017 | 79.17M |
| December 31, 2016 | 50.68M |
| December 31, 2015 | 30.61M |
| December 31, 2014 | 23.03M |
| December 31, 2013 | 18.63M |
| December 31, 2012 | 12.66M |
| December 31, 2011 | 11.52M |
| Date | Value |
|---|---|
| December 31, 2010 | 10.31M |
| December 31, 2009 | 9.84M |
| December 31, 2008 | 5.063M |
| December 31, 2007 | 8.455M |
| December 31, 2006 | 25.68M |
| December 31, 2005 | 5.73M |
| December 31, 2004 | 4.242M |
| December 31, 2003 | 3.596M |
| December 31, 2002 | 2.984M |
| December 31, 2001 | 4.976M |
| December 31, 2000 | 9.553M |
| December 31, 1999 | 2.474M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
203.61M
Minimum
2020
344.50M
Maximum
2023
251.79M
Average
234.27M
Median
2021
SG&A Expense (Annual) Benchmarks
| Cytokinetics Inc | 173.61M |
| Amicus Therapeutics Inc | 275.27M |
| Predictive Oncology Inc | 10.94M |
| Agios Pharmaceuticals Inc | 119.90M |
| Arcutis Biotherapeutics Inc | 185.14M |